Skip to Content

Nadezhda V. Koshkina, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Mechnikov Research, Institute of Vaccines and Sera, Moscow, Russia, PHD, Biochemistry and Immunology
1989 Mendeleev Institute of Chemical Technology, Moscow, Russia, Russian Federation, MS, Biotechnology

Postgraduate Training

1992-1994 Course, Liposome Technology, University of Groningen, N/A, The Netherlands, N/A

Experience/Service

Academic Appointments

Assistant Professor, Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2010
Instructor, Molecular Physiology and Biophysics, Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX, 1997-2002
Postdoctoral Fellow, Bioimmunotherapy, University of Texas MD Anderson Cancer Center, Houston, TX, 1995-1996
Senior Researcher, Division of Preclinical Investigation of Meningococcal Vaccines, Mechnikov Research Institute of Vaccines and Sera, Moscow, 1994-1995
Visiting Scientist, Dept. of Vaccine Development, National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 1994-1995
Visiting Graduate Student, University of Groningen, The Netherlands, 1991-1992

Other Appointments/Responsibilities

Director, Research Training Program for Clinical Fellows, Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, 2002-2010

Institutional Committee Activities

Member, Institutional Faculty Senate, 2012-present
Vice-Chair, Institutional Animal Care & Utilization Committee, 2007-2008
Active Member, Institutional Animal Care & Utilization Committee, 2002-present

Honors and Awards

2013 PSoC NIH Travel Award
2010-2013 NIH Center for Transport Oncophysics Award
2008-2009 Shriver's Sarcoma Initiative Award
2006 Amschwand Sarcoma Cancer Foundation Award
2004 Legends of Friendswood Award for Cancer Research
2002 Golfers Against Cancer Award
1994 Soros Research Award
1992 FEBS Travel Award

Selected Publications

Peer-Reviewed Original Research Articles

1. Koshkina NV, Briggs K, Palalon F, Curley SA. Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by non-invasive radiofrequency field treatment. Cancer. In Press.
2. Koshkina NV, Yang G, Kleinerman ES. Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression. Curr Cancer Drug Targets 13(1):48-56, 2013. e-Pub 1/2013. PMID: 22920438.
3. Raoof M, Cisneros BT, Corr SJ, Palalon F, Curley SA, Koshkina NV. Tumor selective hyperthermia induced by short-wave capacitively-coupled RF elecric-filed. PLoS One 8(7), 2013. PMCID: PMC3701653.
4. Koshkina NV, Rao-Bindal K, Kleinerman ES. Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for treatment of osteosarcoma lung metastases. Cancer 117(15):3457-3467, 2011. PMID: 21287529.
5. Arndt CA, Koshkina NV, Inwards CY, Hawkins DS, Krailo MD, Villaluna D, Anderson PM, Goorin AM, Blakely ML, Bernstein M, Bell SA, Ray K, Grendahl DC, Marina N, Kleinerman ES. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the Children’s Oncology Group. Clin Cancer Res 16(15):4024-4030, 2010. PMID: 20576718.
6. Huang G, Koshkina NV, Kleinerman ES. Fas expression in metastatic osteosarcoma cells is not regulated by CpG island methylation. Oncol Res 18(1):31-9, 2009. PMID: 19911702.
7. Quezada G, Koshkina NV, Zweidler-McKay P, Zhou Z, Kontoyiannis DP, Kleinerman ES. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother 52(2):716-8, 2/2008. PMID: 17984233.
8. Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol 29(12):815-21, 12/2007. PMID: 18090928.
9. Morales-Arias J, Meyers PA, Bolontrade MF, Rodriguez N, Zhou Z, Reddy K, Chou AJ, Koshkina NV, Kleinerman ES. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110(7):1568-1577, 10/2007. PMID: 17694551.
10. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5(10):991-9, 10/2007. PMID: 17951400.
11. Gordon N, Koshkina NV, Jia S-F, Khanna C, Mendoza A, Worth LL, Kleinerman ES. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13(15 Pt 1):4503-4510, 8/2007. PMID: 17671136.
12. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 116:458-63, 9/2005. PMID: 15800950.
13. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27:611-5, 2005. PMID: 16282894.
14. Zhou Z, Lafleur EA, Koshkina NV, Worth LL, Lester MS, Kleinerman ES. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol Cancer Res 3:685-91, 2005. PMID: 16380506.
15. Lafleur EA, Koshkina NV, Stewart J, Jia SF, Worth LL, Duan X, Kleinerman ES. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 10:8114-9, 2004. PMID: 15585647.
16. Koshkina NV, Agoulnik IY, Melton SL, Densmore CL, Knight V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethylenimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8:249-54, 8/2003. PMID: 12907147.
17. Gautam A, Waldrep JC, Densmore CL, Koshkina N, Melton S, Roberts L, Gilbert B, Knight V. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 9(5):353-7, 3/2002. PMID: 11938455.
18. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemother Pharmacol 47:451-6, 2001. PMID: 11391862.
19. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258-62, 2001. PMID: 11595722.
20. Knight V, Kleinerman ES, Waldrep JC, Giovanella BC, Gilbert BE, Koshkina NV. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 922:151-63, 2000. PMID: 11193890.
21. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE, Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 6:2876-80, 2000. PMID: 10914737.
22. Koshkina NV, Gilbert BE, Waldrep JC, Seryshev A, Knight V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother Pharmacol 44:187-92, 1999. PMID: 10453719.
23. Petrov AB, Kolenko VM, Koshkina NV, Zakirov MM, Bugaev LV, Semenova IB, Wiertz EJ, Poolman JT. Non-specific modulation of the immune response with liposomal meningococcal lipopolysaccharide: role of different cells and cytokines. Vaccine 12:1064-70, 1994. PMID: 7998414.
24. Trubetskoy VS, Koshkina NV, Omel'yanenko VG, L'Vov V L, Dmitriev BA, Petrov AB, Torchilin VP. FITC-labeled lipopolysaccharide: use as a probe for liposomal membrane incorporation studies. FEBS Lett 269:79-82, 1990. PMID: 2117560.

Grant & Contract Support

Title: Evaluation of transfer phenomena in cancer cells as a function of RF treatment
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2013 - 9/1/2015
 
Title: Probing transport properties in human hepatocellular carcinoma and pancreatic cancer via multiphysics approach
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 9/1/2013 - 9/1/2015
 
Title: Optimization of gold nanoparticle delivery to pancreatic tumors
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/2011 - 10/1/2013
 
Title: Epigenetic Regulation of Fas in osteosarcoma by HDAC inhibitors
Funding Source: Amschwand Sarcoma Cancer Foundation
Role: Principal Investigator
Duration: 3/1/2010 - 3/1/2012
 
Title: The role of CIP4 in bone sarcoma metastases
Funding Source: Liddy Shriver Sarcoma Initiative
Role: Principal Investigator
Duration: 3/1/2008 - 9/1/2009
 
Title: The role of cytoskeleton-regulatory mechanisms of osteosarcoma metastases
Funding Source: Amschwand Sarcoma Cancer Foundation
Role: Principal Investigator
Duration: 12/31/2007 - 3/1/2011
 
Title: Fas as a novel target for lung metastases therapy
Funding Source: Business Professional Woman/Texas Award
Role: Principal Investigator
Duration: 7/1/2007 - 6/30/2008
 
Title: The Fas pathway in osteosarcoma
Funding Source: Amschwand Sarcoma Cancer Foundation
Role: Principal Investigator
Duration: 8/1/2006 - 7/31/2007
 
Title: Aerosol gemcitabine as a novel approach for the treatment of osteosarcoma metastases in the lungs.
Funding Source: Golfers Against Cancer Foundation
Role: Principal Investigator
Duration: 4/1/2003 - 8/31/2006

Last updated: 10/22/2013